Marksans Pharma (MARKSANS) Share Price Falls 5.37% as Market Cap Stands at Rs 15,026.91 Cr
- September 30, 2026
- Posted by: Kunal Singla
- Category: News
Marksans Pharma Share Price was under pressure in intraday trade on 30 September 2026, with the stock last traded at Rs 324.40 after a 5.37% decline from the previous close of Rs 342.80. The company’s market capitalisation stood at Rs 15,026.91 crore, placing it in the Mid Cap category. For investors tracking Marksans Pharma Share Price Today, the move is significant because it came from a firm opening and failed to hold above the morning high. The price move is confirmed in Univest data; a company-specific reason has not been established. The latest Marksans Pharma Stock News therefore centres on price action, valuation and sector comparison rather than a verified event trigger.
The decline also matters because Marksans Pharma Share Price remains part of the healthcare pack, where valuation and earnings quality often shape market interest. The stock’s current reading near Rs 324 makes Marksans Pharma Share Price Today a useful case study in how a Mid Cap pharmaceuticals name can reprice within a single morning without a fresh operating update. Univest data shows the move clearly, but the reason for the fall is not attributed to any specific corporate development. That keeps the focus on verified numbers, not conjecture, in Marksans Pharma Share Price analysis.
Marksans Pharma (MARKSANS) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 324.4 |
| Previous Close | Rs 342.8 |
| Today's Move | -Rs 18.40 (-5.37%) |
| Open | Rs 344.35 |
| High | Rs 345.9 |
| Low | Rs 323.35 |
| Market Capitalisation | Rs 15,026.91 crore |
| Market Cap Category | Mid Cap |
Marksans Pharma Share Price opened at Rs 344.35, moved to a high of Rs 345.90 and touched a low of Rs 323.35 before last trading at Rs 324.40. Compared with the previous close of Rs 342.80, the stock was down Rs 18.40 or 5.37%. The intraday range shows that Marksans Pharma Share Price Today moved sharply lower after the open and then remained near the day’s lower end. The stock’s market capitalisation of Rs 15,026.91 crore keeps it firmly in the Mid Cap bracket, which is relevant when reading Marksans Pharma Share Price movement alongside other healthcare names.
For Marksans Pharma Share Price, the important verified point is the size of the gap between the opening level and the later trading level. The stock started above the previous close, but the price action did not sustain that early strength. Marksans Pharma Share Price Today therefore reflects a clear intraday decline, with no need to stretch beyond the numbers. According to latest Univest figures, the fall is confirmed, and the price action itself is the main story. That sets up the next question in Marksans Pharma Share Price analysis: whether the fundamentals and valuation justify the market’s attention.
Marksans Pharma (MARKSANS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,026.91 crore |
| P/E Ratio | 30.06x |
| P/B Ratio | 4.89x |
| ROE | 15.31% |
| ROCE | 21.1% |
| EPS | Rs 11.4 |
| Book Value Per Share | Rs 70.16 |
| Dividend Yield | 0.26% |
Marksans Pharma Fundamental Analysis begins with valuation. The stock trades at a P/E ratio of 30.06 and a P/B ratio of 4.89, while ROE stands at 15.31% and ROCE at 21.10%. EPS is Rs 11.40, book value is Rs 70.16, and dividend yield is 0.26%. These numbers show that Marksans Pharma Share Price is being assessed against earnings, accounting value and return generation at the same time. EPS tells investors how much earnings are attributable to each share, book value per share shows the accounting net worth behind each share, and dividend yield gives the historical payout relative to the current price.
Marksans Pharma Share Price also needs to be read in the context of its Mid Cap size and Rs 15,026.91 crore market capitalisation. Within Marksans Pharma Stock Analysis, ROCE above 21% is an important verified strength because it shows the company is generating returns on employed capital above many industry medians. At the same time, the P/B multiple of 4.89 places Marksans Pharma Share Price at a premium to book value, so investors are likely looking at return quality and earnings rather than just asset backing. According to Univest data, Marksans Pharma Share Price moves should therefore be judged through valuation and return metrics, not through unsupported assumptions about the day’s fall.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 30.06x |
| Benchmark Median P/E | 32.43x |
| Benchmark Average P/E | 49.46x |
| Benchmark P/E Range | 3.4x to 699.02x |
| Company P/B Ratio | 4.89x |
| Benchmark Median P/B | 2.89x |
| Benchmark Average P/B | 4.38x |
| Company ROE | 15.31% |
| Benchmark Median ROE | 11.7% |
| Benchmark Average ROE | 10.68% |
| Company ROCE | 21.1% |
| Benchmark Median ROCE | 13.61% |
| Benchmark Average ROCE | 13.4% |
| Company Market Capitalisation | Rs 15,026.91 crore |
| Benchmark Median Market Cap | Rs 776.09 crore |
| Benchmark Average Market Cap | Rs 14,255.4 crore |
In the Healthcare sector and the Pharmaceuticals & Drugs industry, Marksans Pharma Share Price can be compared against a benchmark universe of 199 companies. The company’s P/E of 30.06 is below the industry median of 32.43 and well below the industry average of 49.46. Its P/B of 4.89 is above the sector median of 2.89 and above the average of 4.38. ROE of 15.31% is above the industry median of 11.70% and above the average of 10.68%, while ROCE of 21.10% is also above the median of 13.61% and the average of 13.40%.
That sector backdrop helps frame Marksans Pharma Share Price Today. The stock is not the lowest-valued in the industry on a book basis, but its earnings return profile is stronger than the benchmark middle. The benchmark scope matters because it sets the exact comparison set: 199 same-industry companies, with a market-cap median of Rs 776.09 crore and an average of Rs 14,255.40 crore. Marksans Pharma Share Price therefore sits in a company-size band above the industry median and slightly above the industry average market capitalisation, which is useful context for Marksans Pharma Stock News and Marksans Pharma Fundamental Analysis alike. In simple terms, the valuation is not detached from peers, but the return metrics sit on the better side of the benchmark distribution.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,477.63 | 36.9 | 5.16 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,53,031.38 | 85.99 | 14.24 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,85,216.32 | 85.72 | 20.83 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,20,897.46 | 26.42 | 4.42 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,12,205.15 | 33.15 | 3.18 | 11.83 | 16 |
Marksans Pharma Share Price can be better understood by comparing it with listed healthcare peers. On market capitalisation, Marksans Pharma at Rs 15,026.91 crore is smaller than Sun Pharmaceutical Industries at Rs 4,41,477.63 crore, Divi’s Laboratories at Rs 2,53,031.38 crore and Torrent Pharmaceuticals at Rs 1,85,216.32 crore, but larger than Zydus Lifesciences at Rs 1,20,897.46 crore and Cipla at Rs 1,12,205.15 crore. That places Marksans Pharma Share Price in a mid-tier peer position inside the listed set.
On valuation, Marksans Pharma Share Price at a P/E of 30.06 is below Sun Pharmaceutical Industries at 36.90, far below Divi’s Laboratories at 85.99 and Torrent Pharmaceuticals at 85.72, but above Zydus Lifesciences at 26.42. Its P/B of 4.89 is lower than Sun Pharmaceutical Industries at 5.16, much lower than Divi’s Laboratories at 14.24 and Torrent Pharmaceuticals at 20.83, yet higher than Zydus Lifesciences at 4.42 and Cipla at 3.18. ROE and ROCE at 15.31% and 21.10% place Marksans Pharma Share Price above Cipla on both measures and close to several stronger-return names. Univest data makes the relative picture clear: the stock is neither the lowest-valued nor the most expensive in the group, but it does sit above some peers on return metrics.
Why Investors Are Watching Marksans Pharma
- Marksans Pharma Share Price fell 5.37% in intraday trade and moved from an opening of Rs 344.35 to a last traded price of Rs 324.40.
- The stock’s market capitalisation of Rs 15,026.91 crore keeps Marksans Pharma Share Price in the Mid Cap category.
- Marksans Pharma Fundamental Analysis shows a P/E of 30.06, P/B of 4.89, ROE of 15.31% and ROCE of 21.10%.
- The company’s P/E is below the industry median, while ROE and ROCE are above the same-industry median and average.
- Marksans Pharma Share Price sits in a peer set where valuation and return metrics vary widely across listed pharmaceuticals names.
About Marksans Pharma
Marksans Pharma operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is part of the Mid Cap segment by market capitalisation and is valued by the market through earnings, book value and return ratios. Marksans Pharma Share Price is therefore tied to a business profile that investors typically read through product execution, earnings quality and capital efficiency rather than only through size. The stock’s core context is pharmaceutical and healthcare-linked, which makes peer comparison and valuation especially relevant for Marksans Pharma Stock News and Marksans Pharma Share Price analysis.
For readers following Marksans Pharma Share Price Today, the key company-level takeaways are the sector, the industry and the financial ratios already visible in market data. That is enough to place the stock within the wider healthcare universe without adding unsupported assumptions about operations or product mix. According to latest Univest figures, Marksans Pharma Share Price should be assessed as a Mid Cap pharmaceutical name with above-median returns on equity and capital employed.
Track Marksans Pharma Share Price on Univest
Use Marksans Pharma (MARKSANS) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Investors can track Marksans Pharma Share Price on Univest for live updates, key valuation ratios, 52-week levels, market cap context and broader stock insights. Univest also presents Marksans Pharma Stock News, Marksans Pharma Share Price Today and Marksans Pharma Fundamental Analysis in one place, helping readers follow price action and company metrics together. For users who want a cleaner view of Marksans Pharma Share Price Live, the platform keeps the focus on verified market numbers and company fundamentals.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why did Marksans Pharma Share Price fall today?
Ans. Marksans Pharma Share Price fell 5.37% to Rs 324.40 in intraday trade. The price move is confirmed in Univest data; a company-specific reason has not been established. The move is best read through verified price action.
What is Marksans Pharma Share Price Today?
Ans. Marksans Pharma Share Price Today stood at Rs 324.40. It was lower than the previous close of Rs 342.80 and traded between Rs 323.35 and Rs 345.90 during the morning session.
What is Marksans Pharma market capitalisation?
Ans. Marksans Pharma has a market capitalisation of Rs 15,026.91 crore. That places it in the Mid Cap category and gives useful context for Marksans Pharma Share Price compared with other healthcare names.
What are the key valuation ratios for Marksans Pharma Share Price?
Ans. Marksans Pharma Share Price is supported by a P/E ratio of 30.06 and a P/B ratio of 4.89. These numbers show how the market is valuing earnings and book value in the current trading setup.
How do ROE and ROCE compare for Marksans Pharma?
Ans. Marksans Pharma reports ROE of 15.31% and ROCE of 21.10%. Both are above the industry median and average, which gives Marksans Pharma Share Price a stronger return profile than several same-industry peers.
How does Marksans Pharma compare with healthcare peers?
Ans. Marksans Pharma Share Price sits below Sun Pharmaceutical Industries, Divi's Laboratories and Torrent Pharmaceuticals on market cap, but above Zydus Lifesciences and Cipla on return metrics such as ROE and ROCE.
What does the book value tell investors about Marksans Pharma?
Ans. Marksans Pharma has a book value of Rs 70.16 per share. Book value per share shows the accounting net worth behind each share, and it gives a useful reference point alongside Marksans Pharma Share Price and P/B ratio.
Should investors track Marksans Pharma Share Price on Univest?
Ans. Yes, investors tracking Marksans Pharma Share Price can use Univest for live price movement, valuation ratios, market capitalisation, 52-week levels and healthcare-sector context. It helps connect price action with fundamentals in one view.
